Sharekhan has given Buy recommendation for Laurus Labs with a target price of Rs. 450 in its research report issued on Mar 10, 2021

Sharekhan’s research report on Laurus Labs

Formulations business on a strong footing to grow backed by opportunities in the US while diversification to non ARV areas – anti diabetics and cardiology to fuel API growth. Sturdy growth prospects, visibility on earnings, healthy return ratios and low debt-equity are the key positives. Over a long term horizon of 3-5 years, Laurus has charted out its growth trajectory encompassing all segments & management aspires grow its revenues beyond $1bn in size.


We retain a Buy recommendation on Laurus Labs Limited (Laurus) with a revised PT of Rs. 450.